Mitotane(Lsodren)

立即咨询

Mitotane(Lsodren)

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

53-19-0

包装与价格：

包装	价格(元)
10mM (in 1mL DMSO)	电议
100mg	电议
500mg	电议

产品介绍

Mitotane (Lsodren) (2,4′-DDD) 是 DDD 的异构体和二氯二苯基三氯乙烷 (DDT) 的衍生物，是一种抗肿瘤剂，可用于研究肾上腺皮质癌。 Mitotane (Lsodren) 至少部分通过细胞内游离胆固醇 (FC) 积累诱导的脂毒性发挥其肾上腺皮质溶解作用。 Mitotane (Lsodren) 对促肾上腺皮质激素细胞有直接的垂体作用。 Mitotane (Lsodren) 可通过类固醇和异生素受体 (SXR) 激活诱导 CYP3A4 基因表达，并具有药物-药物相互作用。

Cas No.	53-19-0
别名	米托坦; 2,4′-DDD; o,p'-DDD
化学名	1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene
Canonical SMILES	C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl
分子式	C₁₄H₁₀Cl₄
分子量	320.04
溶解度	≥ 12.5mg/mL in DMSO
储存条件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
产品描述	Mitotane(2,4′-DDD), an isomer of DDD and derivative of DDT, is an antineoplastic medication used in the treatment of adrenocortical carcinoma.IC50 value: Target: Mitotane alters steroid peripheral metabolism, directly suppresses the adrenal cortex and alters cortisone metabolism leading to hypocortisolism. Side effects as reported by Schteinberg et al. include anorexia and nausea (88%), diarrhea (38%), vomiting (23%), decreased memory and ability to concentrate (50%), rash (23%), gynecomastia (50%), arthralgia (19%), and leukopenia (7%). References: [1]. Gentilin E, Tagliati F, Terzolo M, Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function. J Endocrinol. 2013 Jul 29;218(3):275-285. [2]. Lehmann TP, Wrzesiński T, Jagodziński PP. The effect of mitotane on viability, steroidogenesis and gene expression in NCI H295R adrenocortical cells. Mol Med Rep. 2013 Mar;7(3):893-900. [3]. Takeshita A, Igarashi-Migitaka J, Koibuchi N, Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor. J Endocrinol. 2013 Feb 15;216(3):297-305. [4]. Ederhy S, Cohen A, Dufaitre G, No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma. J Endocrinol Invest. 2012 Nov;35(10):911-4. [5]. Alexandraki KI, Kaltsas GA, le Roux CW, Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clin Endocrinol (Oxf). 2010 Mar;72(3):305-11.